0001179110-20-010900.txt : 20201106
0001179110-20-010900.hdr.sgml : 20201106
20201106182801
ACCESSION NUMBER: 0001179110-20-010900
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201104
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chapman Steven Leonard
CENTRAL INDEX KEY: 0001711968
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37478
FILM NUMBER: 201295574
MAIL ADDRESS:
STREET 1: 201 INDUSTRIAL ROAD, SUITE 410
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Natera, Inc.
CENTRAL INDEX KEY: 0001604821
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 010894487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 INDUSTRIAL ROAD
STREET 2: SUITE 410
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-249-9090
MAIL ADDRESS:
STREET 1: 201 INDUSTRIAL ROAD
STREET 2: SUITE 410
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
4
1
edgar.xml
FORM 4 -
X0306
4
2020-11-04
0
0001604821
Natera, Inc.
NTRA
0001711968
Chapman Steven Leonard
C/O NATERA, INC., 201 INDUSTRIAL ROAD
SUITE 410
SAN CARLOS
CA
94070
1
1
0
0
Chief Executive Officer
Common Stock
2020-11-04
4
M
0
2188
9.59
A
39088
D
Common Stock
2020-11-04
4
M
0
4468
10.41
A
43556
D
Common Stock
2020-11-04
4
M
0
2083
10.73
A
45639
D
Common Stock
2020-11-04
4
M
0
6105
9.29
A
51744
D
Common Stock
2020-11-04
4
M
0
3125
13.01
A
54869
D
Common Stock
2020-11-04
4
M
0
13541
20.27
A
68410
D
Common Stock
2020-11-04
4
S
0
36115
75
D
32295
D
Common Stock
2020-11-04
4
M
0
20312
13.01
A
52607
D
Common Stock
2020-11-04
4
S
0
25236
75
D
27371
D
Stock Option (right to buy)
9.59
2020-11-04
4
M
0
2188
0
D
2026-04-07
Common Stock
2188
0
D
Stock Option (right to buy)
10.41
2020-11-04
4
M
0
4468
0
D
2027-06-08
Common Stock
4468
23461
D
Stock Option (right to buy)
10.73
2020-11-04
4
M
0
2083
0
D
2027-07-13
Common Stock
2083
10417
D
Stock Option (right to buy)
9.29
2020-11-04
4
M
0
6105
0
D
2028-03-08
Common Stock
6105
67156
D
Stock Option (right to buy)
13.01
2020-11-04
4
M
0
3125
0
D
2029-01-10
Common Stock
3125
66666
D
Stock Option (right to buy)
20.27
2020-11-04
4
M
0
13541
0
D
2029-04-11
Common Stock
13541
71875
D
Stock Option (right to buy)
13.01
2020-11-04
4
M
0
20312
0
D
2020-01-10
Common Stock
20312
81250
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2019 as amended on February 28, 2020. The Reporting Person is subject to a Lock-up Letter Agreement that expires on November 10, 2020. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
These reported shares are subject to restrictions in the Lock-Up Letter Agreement.
The option shares vest over four years. 25% of the option shares vested and became exercisable on April 1, 2017 and the remaining shares vest in 36 equal monthly installments thereafter.
The option shares vest over four years. 25% of the option shares vested and became exercisable on March 21, 2018 and the remaining shares vest in 36 equal monthly installments thereafter.
The option shares vest over four years. 25% of the option shares vested and became exercisable on March 12, 2018 and the remaining shares vest in 36 equal monthly installments thereafter.
The option shares vest over four years. 25% of the option shares vested and became exercisable on March 9, 2019 and the remaining shares vest in 36 equal monthly installments thereafter.
The option shares vest over four years. 25% of the option shares vested and became exercisable on January 2, 2020 and the remaining shares vest in 36 equal monthly installments thereafter.
The option shares vest over four years. 25% of the option shares vested and became exercisable on March 22, 2020 and the remaining shares vest in 36 equal monthly installments thereafter.
This option becomes exercisable, if at all, upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. The first milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $2,000,000,000 and (ii) the Issuer's outstanding shares as most recently reported on the Issuer's Form 10-Q or Form 10-K (the "Capitalization"). The second milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $3,000,000,000 and (ii) the Capitalization (the "Performance Vesting Conditions"). As of June 23, 2020, the Company's Board of Director determined the performance criteria had been met with respect to 18,750 additional shares.
/s/ Tami Chen, attorney-in-fact
2020-11-06